PLMO Pulmo BioTech Inc. featured news, full reports, and detailed charts
Pulmo BioTech Inc. (PLMO/PLMO.OB) Wrap Up:
Pulmo BioTech, Inc., through its subsidiary, PulmoScience, Inc., engages in developing a non-invasive molecular imaging technique for the diagnosis of pulmonary embolism, pulmonary hypertension, and lung inflammatory diseases under the trade name PulmoBind. The PulmoBind uses an intravenously delivered radionuclide tagged molecule, which specifically bonds to the inner walls of the circulatory system in the lungs, and by the use of an external Gamma Camera allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician. It is under the regulatory approval process for Phase I human trials. The company was founded in 2006 and is based in New York...www.pulmobiotech.com
Founded in 2006
Pulmo BioTech Inc. (PLMO:OTC Bulletin Board Market)
LAST $0.27 USD
CHANGE TODAY -0.01 -3.57%
VOLUME 19.5K
As of 3:48 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Pulmo BioTech Inc. (PLMO)
|
OPEN
$0.28
|
PREVIOUS CLOSE
$0.28
|
|
|
DAY HIGH
$0.28
|
DAY LOW
$0.27
|
|
|
52 WEEK HIGH
03/24/09 - $6.00
|
52 WEEK LOW
11/10/09 - $0.23
|
|
|
MARKET CAP
14.2M
|
AVERAGE VOLUME 3 mo
140.9K
|
|
|
DILUTED EPS TTM
$-0.0091
|
SHARES OUTSTANDING
52.6M
|
|
|
PLMO Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
PLMO Top Compensated Officers
No compensation data is available at this time for the top officers at this company.
Executives, Board Directors
Key developments for Pulmo BioTech Inc. (PLMO)
Pulmo Biotech Inc. Announces Experimental Results of PulmoBind
11/11/2009
Pulmo BioTech Inc. has announced that early experimental results have indicated that its PulmoBind(TM) product candidate can be potentially used for the early detection and follow-up of many conditions that affect the physical and/or biological integrity of the Pulmonary Circulation. These early results, if confirmed by further experiments, would broaden the range of conditions that PulmoBind(TM) is able to diagnose.
Pulmo BioTech Inc. Announces Further Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
10/21/2009
Pulmo BioTech Inc. has announced has announced further details of its non-binding letter of intent with Biotechnology Consulting Poland Sp. z.o.o. to license its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) development work, clinical trials and ultimately, commercialization in the European market. Biotechnology Consulting Poland will license the technology of PulmoBind(TM) from Pulmo BioTech pursuant to a License Agreement expected to be entered into before the end of 2009. This will enable Biotechnology Consulting Poland to carry out Phase I trials in Europe starting in early 2010. Once these safety and efficacy trials are completed and if approval has been granted by the European Regulatory Authority it is intended that Biotechnology Consulting Poland will immediately commence Phase II/III trials for PulmoBind(TM) against the conditions of pulmonary hypertension and pulmonary embolism. Pursuant to the License Agreement, Biotechnology Consulting Poland will ultimately be responsible for the commercialization of PulmoBind(TM) across the whole of the European Union and the European Economic Area. It is contemplated that the License Agreement will have an initial term of six years, with an extension clause, and during this period Pulmo BioTech will provide all of the technical information and resources necessary to enable Biotechnology Consulting Poland to successfully complete all of its European trials work. By utilizing the technical and commercial skills of Biotechnology Consulting Poland, Pulmo BioTech will have European trials of PulmoBind(TM) in tandem with the work in North America, which will permit Pulmo BioTech to complete trials and begin commercialization in parallel across these two continents.
Pulmo BioTech Inc. Reports Earnings Results for the Quarter Ended June 30, 2009
08/20/2009
Pulmo BioTech Inc. reported earnings results for the quarter ended June 30, 2009. Net loss for the quarter was $95,607, up from $230,389 for the same quarter the previous year.
PLMO Competitors
| Company | Last | Change | |
| No competitor information is available for PLMO. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | PLMO | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
PLMO |
||
|
PLMO transactions
| Type Date |
Target |
|
Private Placement
June 15, 2009 |
-- |
More Recent News About Pulmo BioTech Inc.
More news for PLMO
PULMO BIOTECH INC. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Forward-looking Statements The statements made in this Quarterly Report which are not purely historical are forward-looking statements with respect to the goals, plan objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company, including, without limitation, (i) the Company's ability to raise capital, and (ii) statements preceded by, followed by or that include the words "may", "would", "could", "should", "expects", "projects", "anticipates", "believes", "estimates", "plans", "intends", "targets" or similar expressions. Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond the Company's control) that could cause actual results to differ materially from those set forth in the forward-looking statements, including the following, general economic or industry conditions, nationally and/or in the communities in which the Company may conduct business, changes in the interest rate environment, legislation or regulatory requirements, conditions of the securities markets, the Company's ability to raise capital, changes in accounting principles, policies or guidelines, financial or political instability, acts of war or terrorism, other economic, competitive, governmental, regulatory and technical factors affecting the Company's operations, products, services and prices. Accordingly, results actually achieved may differ materially from expected results in these statements. Forward-looking statements speak only as of the date they are made. The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statement. Plan o...Click here to read the whole Article (external link)
Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of t
NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB; Frankfort Borse: PBO) has announced that early experimental results have indicated that its PulmoBind(TM) product candidate can be potentially used for the early detection and follow-up of many conditions that affect the physical and/or biological integrity of the Pulmonary Circulation. These early results, if confirmed by further experiments, would broaden the range of conditions that PulmoBind(TM) is able to diagnose. "We are very pleased with these early results. To date, we have mainly concentrated on the use of PulmoBind(TM) as a diagnostic agent for Pulmonary Hypertension (PH) and Pulmonary Embolism (PE). While our work in these areas continues, early experimental results have indicated that PulmoBind(TM) could be used to diagnose a wide range of Pulmonary Vascular diseases associated with lung disorders, heart disease and connective tissue disease. For example, lung disorders associated with HIV, Cirrhosis and Shistosomiasis are all conditions that we believe could potentially be diagnosed using PulmoBind(TM). If our experimental results can be confirmed, then PulmoBind(TM) has great potential as a front-line test to either confirm or exclude disorders of the Pulmonary Circulation in patients who present with "shortness of breath". PulmoBind(TM) could also help in predicting outcomes in these patients and guiding their therapy." - Garry McCann, CEO Pulmo BioTech Inc.About Pulmo BioTech Inc.Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize...Click here to read the whole Article (external link)
Pulmo BioTech Inc. Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
NEW YORK, Oct. 23 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; Frankfort Borse: PBO) has announced that it will ultimately receive at least $3.3 million pursuant to the license agreement contemplated by the previously announced non-binding letter of intent with Biotechnology Consulting Poland Sp. z.o.o. with respect to its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) development work, clinical trials and ultimately, commercialization in the European market. "We are pleased that the relationship with Biotechnology Consulting Poland to be finalized in a license agreement expected before the end of 2009 will allow Pulmo BioTech to bring PulmoBind(TM) to the whole of the European Union and European Economic Area. Under the contemplated license agreement, Pulmo BioTech will be providing all of the technical resources to enable this to happen, and in return Biotechnology Consulting Poland will be providing a substantial cash element to Pulmo BioTech. Biotechnology Consulting Poland will license the technology to enable them to carry out all of the trials necessary to gain European Approval for PulmoBind(TM) with the intention that they will then commercialize PulmoBind across Europe. By following this parallel approach with Pulmo BioTech concentrating on the North American market and Biotechnology Consulting Poland having responsibility for Europe, we expect to minimize the time required to complete trials and, provided that regulatory approval is ultimately obtained, to gain maximum sales for PulmoBind(TM) across both these major markets to the benefit of our shareholders and the medical community." - Garry McCann, CEO Pulmo BioTech Inc.About Pulmo BioTech Inc.Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive c...Click here to read the whole Article (external link)
Pulmo BioTech Inc. Announces Further Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) to the European Market
NEW YORK, Oct. 21 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; Frankfort Borse: PBO) has announced has announced further details of its non-binding letter of intent with Biotechnology Consulting Poland Sp. z.o.o. to license its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) development work, clinical trials and ultimately, commercialization in the European market. "Biotechnology Consulting Poland will license the technology of PulmoBind(TM) from Pulmo BioTech pursuant to a License Agreement expected to be entered into before the end of 2009. This will enable Biotechnology Consulting Poland to carry out Phase I trials in Europe starting in early 2010. Once these safety and efficacy trials are completed and if approval has been granted by the European Regulatory Authority it is intended that Biotechnology Consulting Poland will immediately commence Phase II/III trials for PulmoBind(TM) against the conditions of pulmonary hypertension and pulmonary embolism. Pursuant to the License Agreement, Biotechnology Consulting Poland will ultimately be responsible for the commercialization of PulmoBind(TM) across the whole of the European Union and the European Economic Area. It is contemplated that the License Agreement will have an initial term of six years, with an extension clause, and during this period Pulmo BioTech will provide all of the technical information and resources necessary to enable Biotechnology Consulting Poland to successfully complete all of its European trials work. By utilizing the technical and commercial skills of Biotechnology Consulting Poland, Pulmo BioTech will have European trials of PulmoBind(TM) in tandem with the work in North America, which will permit Pulmo BioTech to complete trials and begin commercialization in parallel across these two continents." - Garry McCann, CEO Pulmo BioTech ...Click here to read the whole Article (external link)
CEO Interview: Intellect Neurosciences, Inc. - Dr. Daniel G. Chain
67 WALL STREET, New York - October 20, 2009 - The Wall Street Transcript has just published its Biotechnology Report offering a timely review of the sector to serious investors and industry executives. This 70-page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Heightened M&A Activity - Trend Toward Orphan Disease Drug Development - Generic Drug Competition - Current Length Of FDA Approval Process - Ownership Ego Preventing Shareholder Returns - IPO And Secondary Offering Window Opening - Big Pharma R&D Pipeline - Decreased Clinical Development Risk - Impact Of Health Care Reform - Convergence Of Large-Cap Biotech And Pharmaceutical Companies - Easier Credit For Small Cap Biotech Companies - Developments In Cancer Chemotherapeutics - Gene Delivery Technology Companies include: ADVENTRX (ANX); Abbott Labs (ABT); Advaxis (ADVX); Amedisys (AMED); Amgen (AMGN); Amylin Pharmaceuticals (AMLN); Antares Pharma (AIS); BioDelivery Sciences (BDSI); Biogen Idec (BIIB); Biomarin (BMRN); Boston Scientific (BSX); Bristol Myers (BMY); CVS Caremark (CVS); Celgene (CELG); Cerner (CRN); Cerus (CERS); Coke (KO); CombiMatrix (CBMX); Coventry Health Care (CVH); DARA (DARA); Eisai (ESALY); Eli Lilly (LLY); GenVec (GNVC); Gilead (GILD); GlaxoSmithKline (GSK); Health Management Associates (HMA); Human Genome Sciences (HGSI); Inspire Pharmaceuticals (ISPH); Intellect Neurosciences (ILNS.OB); InterMune (ITMN); International Stem Cel...Click here to read the whole Article (external link)
Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM)
NEW YORK, Oct. 20 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; Frankfort Borse: PBO) has announced that it has entered into a non-binding letter of intent with BioTechnology Consulting Poland Sp. z.o.o. to license its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) for development work, clinical trials and ultimately, commercialization in the European market. "We are very pleased to have signed a non-binding LOI with BioTechnology Consulting Poland. The license agreement contemplated by the LOI will allow Pulmo BioTech to continue with its focus on achieving regulatory approval for PulmoBind in North America while ensuring that European phase trials will be carried out in parallel, allowing rapid entry to the European Market as well as the United States. Under the License Agreement, BioTechnology Consulting Poland will be responsible for all European phase trials and subsequent commercialization across the whole of the European Union and European Economic Area. Further details as to the specifics of this LOI are expected to be announced shortly." - Garry McCann, CEO Pulmo BioTech Inc.About Pulmo BioTech Inc.Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stockholders.ISIN: US7458451074CUSIP: 745845107WKN: A0RDTZAbout PulmoScience Inc.PulmoScience Inc. was established in 2006, and is currently developing...Click here to read the whole Article (external link)
PULMO BIOTECH INC. Financials
PERIOD ENDING30-Jun-0931-Mar-0931-Dec-0830-Sep-08Total Revenue - - - - Cost of Revenue - - - - Gross Profit - - - - Operating ExpensesResearch Development35 85 33 95 Selling General and Administrative81 74 76 122 Non Recurring - - - - Others - - - - Total Operating Expenses - - - - Operating Income or Loss(116)(159)(109)(218)Income from Continuing OperationsTotal Other Income/Expenses Net - - - - Earnings Before Interest And Taxes(116)(159)(109)(218)Interest Expense - - - - Income Before Tax(116)(159)(109)(218)Income Tax Expense(2)1 4 (19)Minority Interest - - - - Net Income From Continuing Ops(114)(160)(113)(199)Non-recurring EventsDiscontinued Operations - - - - Extraordinary Items - - - - Effect Of Accounting Changes - - -...Click here to read the whole Article (external link)
PULMO BIOTECH INC. Files SEC form 10-Q, Quarterly Report
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Forward-looking Statements The statements made in this Quarterly Report which are not purely historical are forward-looking statements with respect to the goals, plan objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company, including, without limitation, (i) the Company's ability to raise capital, and (ii) statements preceded by, followed by or that include the words "may", "would", "could", "should", "expects", "projects", "anticipates", "believes", "estimates", "plans", "intends", "targets" or similar expressions. Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond the Company's control) that could cause actual results to differ materially from those set forth in the forward-looking statements, including the following, general economic or industry conditions, nationally and/or in the communities in which the Company may conduct business, changes in the interest rate environment, legislation or regulatory requirements, conditions of the securities markets, the Company's ability to raise capital, changes in accounting principles, policies or guidelines, financial or political instability, acts of war or terrorism, other economic, competitive, governmental, regulatory and technical factors affecting the Company's operations, products, services and prices. Accordingly, results actually achieved may differ materially from expected results in these statements. Forward-looking statements speak only as of the date they are made. The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statement. Plan o...Click here to read the whole Article (external link)
PULMO BIOTECH INC. Files SEC form 10-K, Annual Report
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operation. Forward-looking Statements Statements made in this Annual Report which are not purely historical are forward-looking statements with respect to the goals, plan objectives, intentions, expectations, financial condition, results of operations, future performance and business of our Company, including, without limitation, (i) our ability to raise capital, and (ii) statements preceded by, followed by or that include the words "may", "would", "could", "should", "expects", "projects", "anticipates", "believes", "estimates", "plans", "intends", "targets" or similar expressions. Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond our Company's control) that could cause actual results to differ materially from those set forth in the forward-looking statements, including the following: general economic or industry conditions, nationally and/or in the communities in which our Company conducts business, changes in the interest rate environment, legislation or regulatory requirements, conditions of the securities markets, our ability to raise capital, changes in accounting principles, policies or guidelines, financial or political instability, acts of war or terrorism, other economic, competitive, governmental, regulatory and technical factors affecting our Company's operations, products, services and prices. Accordingly, results actually achieved may differ materially from expected results in these statements. Forward-looking statements speak only as of the date they are made. Our Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements. Going Concern ...Click here to read the whole Article (external link)
PULMO BIOTECH INC. Files SEC form 8-K, Regulation FD Disclosure
Show all filings for PULMO BIOTECH INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for PULMO BIOTECH INC. 15-Jun-2009Regulation FD Disclosure Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended f...Click here to read the whole Article (external link)
Would you like to leave a comment about Pulmo BioTech Inc. PLMO/PLMO.OB
Find out what social network information about Pulmo BioTech Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Pulmo BioTech Inc. there is more great information available at Realpennies.com